Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Vascul Pharmacol ; 81: 61-8, 2016 06.
Article in English | MEDLINE | ID: mdl-27073025

ABSTRACT

Production of NO by the endothelial nitric oxide synthase (eNOS) has a major role in blood pressure control and suppression of atherosclerosis. In a previous study, we presented evidence implicating the Pin1 prolyl isomerase in negative modulation of eNOS activity in bovine aortic endothelial cells (BAECs). Pin1 recognizes phosphoserine/phosphothreonine-proline motifs in target proteins and catalyzes prolyl isomerization at the peptide bond. In the present study, we show, first, with purified proteins, that Pin1 binds to eNOS directly via the Pin1 WW domain. Binding is enhanced by mimicking phosphorylation of eNOS at S116. Interaction of Pin1 with eNOS markedly reduces eNOS enzymatic activity. Second, in BAECs, we show that TNFα induces ERK 1/2-mediated S116 phosphorylation of eNOS, accompanied by Pin1 binding. TNFα treatment of BAECs results in a reduction in NO release from the cells in a manner that depends on the activities of both Pin1 and ERK 1/2. Evidence is also presented that this mechanism of eNOS regulation cannot occur in rat and mouse cells because there is no proline residue in the mouse and rat amino acid sequences adjacent to the putative phosphorylation site. Moreover, we find that phosphorylation of this site is not detectable in mouse eNOS.


Subject(s)
Endothelial Cells/drug effects , Enzyme Inhibitors/pharmacology , NIMA-Interacting Peptidylprolyl Isomerase/metabolism , Nitric Oxide Synthase Type III/antagonists & inhibitors , Nitric Oxide/metabolism , Tumor Necrosis Factor-alpha/pharmacology , Animals , Binding Sites , Cattle , Cells, Cultured , Endothelial Cells/enzymology , Extracellular Signal-Regulated MAP Kinases/metabolism , Humans , Mice , Nitric Oxide Synthase Type III/metabolism , Phosphorylation , Protein Binding , Protein Interaction Domains and Motifs , Rats , Serine , Species Specificity
2.
Vascul Pharmacol ; 59(1-2): 27-35, 2013.
Article in English | MEDLINE | ID: mdl-23727078

ABSTRACT

It has been shown previously that phosphorylation of the endothelial nitric oxide synthase (eNOS) at serine 116 (S116) under basal conditions suppresses eNOS enzymatic activity in endothelial cells. It has also been shown that vascular endothelial growth factor (VEGF) treatment of endothelial cells produces a rapid S116 dephosphorylation, which is blocked by the calcineurin inhibitor, cyclosporin A (CsA). In this study, we show that activation of eNOS in response to a variety of other eNOS-activating agonists and the cytosolic calcium-elevating agent, thapsigargin also involves CsA-inhibitable S116 dephosphorylation. Studies with the purified eNOS enzyme also demonstrate that neither mimicking phosphorylation at S116 nor phosphorylation of the purified enzyme at S116 in vitro has any effect on enzymatic activity. Phospho-mimicking, however, does interfere with the interaction of eNOS with c-Src, an interaction which is known to activate eNOS by phosphorylation at tyrosine 83 (Y83). Agonist-stimulated eNOS-Src complex formation, as well as agonist-stimulated Y83 phosphorylation, are blocked by calcineurin inhibition by CsA and by a cell-permeable calcineurin inhibitory peptide. Taken together, these data suggest a mechanism of eNOS regulation whereby calcineurin-mediated dephosphorylation of eNOS at S116 affects eNOS enzymatic activity indirectly, rather than directly, by facilitating c-Src binding and Y83 phosphorylation.


Subject(s)
Calcineurin/metabolism , Nitric Oxide Synthase Type III/metabolism , Serine/metabolism , Tyrosine/metabolism , Animals , COS Cells , Calcium/metabolism , Cattle , Cyclosporine/pharmacology , Endothelial Cells/drug effects , Endothelial Cells/enzymology , Endothelial Cells/metabolism , Endothelium, Vascular/drug effects , Endothelium, Vascular/enzymology , Endothelium, Vascular/metabolism , Enzyme Inhibitors/pharmacology , Nitric Oxide Synthase Type III/antagonists & inhibitors , Permeability/drug effects , Phosphorylation , Thapsigargin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...